Clinical Trials
84 trialsNCT01787500 2026-04-23
Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02215720 2026-03-20
TORERO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Completed
NCT04290546 2026-02-27
CIML NK Cell in Head & Neck Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT07435311 2026-02-27
A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
R-Pharm
Phase 1 Completed
NCT05040568 2026-01-26
A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03290937 2026-01-06
Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT05668585 2025-11-21
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors
C4 Therapeutics, Inc.
Phase 1 Completed
NCT05954871 2025-11-13
Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer
Genentech, Inc.
Phase 1 Completed
NCT03524326 2025-05-13
Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT04091867 2025-02-24
sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC
University of Colorado, Denver
Phase 1 Completed
NCT03667482 2024-07-23
Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01935921 2023-06-15
Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00593060 2023-05-24
Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer
Massachusetts General Hospital
Phase 1 Completed
NCT02764593 2022-11-29
Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer
RTOG Foundation, Inc.
Phase 1 Completed
NCT02627274 2022-11-22
A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Hoffmann-La Roche
Phase 1 Completed
NCT02857270 2022-11-22
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
Eli Lilly and Company
Phase 1 Completed
NCT03319459 2021-11-22
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Completed
NCT02282371 2021-10-26
Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03360734 2021-07-12
GATTO
Glycotope GmbH
Phase 1 Completed
NCT02095054 2021-04-01
Regorafenib and Cetuximab in Patients With Advanced Malignancy
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00543504 2020-06-30
Bevacizumab in Multiple Phase I Combinations
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02124148 2020-04-01
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01254617 2020-03-13
ADCC
National Cancer Institute (NCI)
Phase 1 Completed
NCT01621217 2020-02-28
NOAC8
Lund University Hospital
Phase 1 Completed
NCT02327169 2020-02-25
A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies
Takeda
Phase 1 Completed
NCT01287130 2019-12-17
AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01445405 2019-12-17
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02938273 2019-12-11
Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)
The Netherlands Cancer Institute
Phase 1 Completed
NCT01758731 2019-09-23
Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History
University of Colorado, Denver
Phase 1 Completed
NCT00501410 2019-08-28
FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02277197 2019-04-18
Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
University of Pittsburgh
Phase 1 Completed
NCT01716416 2019-04-16
HNSCC
Washington University School of Medicine
Phase 1 Completed
NCT01973868 2019-04-09
Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination
Bayer
Phase 1 Completed
NCT02555644 2019-02-15
A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02350712 2018-09-11
Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer
Daiichi Sankyo
Phase 1 Completed
NCT01540682 2018-08-29
MLN8237 in Head and Neck Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT00925015 2018-08-15
Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01285037 2018-02-20
A Study of LY2801653 in Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT00622674 2017-12-02
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT00540943 2017-11-29
Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer
GlaxoSmithKline
Phase 1 Completed
NCT01472016 2017-11-21
Study of ABT-700 in Subjects With Advanced Solid Tumors
AbbVie
Phase 1 Completed
NCT00497497 2017-05-19
A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)
Genentech, Inc.
Phase 1 Completed
NCT02110082 2017-04-19
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
Bristol-Myers Squibb
Phase 1 Completed
NCT01238237 2017-02-01
Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA
Northwell Health
Phase 1 Completed
NCT01482377 2017-01-27
A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin
Hoffmann-La Roche
Phase 1 Completed
NCT00477880 2017-01-10
Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing Stomach Cancer
Vanderbilt University Medical Center
Phase 1 Completed
NCT00671372 2016-11-02
A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer
Genentech, Inc.
Phase 1 Completed
NCT01046266 2016-09-14
A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma
Hoffmann-La Roche
Phase 1 Completed
NCT01451632 2016-09-08
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
Merrimack Pharmaceuticals
Phase 1 Completed
NCT00736619 2016-08-10
Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
Memorial Sloan Kettering Cancer Center
Phase 1 Completed